Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50-Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.69 and traded as low as $3.15. Voyager Therapeutics shares last traded at $3.16, with a volume of 904,679 shares.

Wall Street Analyst Weigh In

A number of brokerages recently commented on VYGR. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, May 26th. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday. Finally, Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Price Performance

The business’s fifty day simple moving average is $3.67 and its two-hundred day simple moving average is $3.84. The company has a market cap of $183.68 million, a PE ratio of -1.54 and a beta of 1.27.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. As a group, analysts predict that Voyager Therapeutics, Inc. will post -1.43 EPS for the current year.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently bought and sold shares of VYGR. Altshuler Shaham Ltd purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at approximately $801,000. EcoR1 Capital LLC increased its holdings in Voyager Therapeutics by 497.2% in the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after acquiring an additional 3,332,544 shares in the last quarter. Chase Investment Counsel Corp purchased a new stake in Voyager Therapeutics in the 1st quarter worth $76,000. Allspring Global Investments Holdings LLC raised its position in Voyager Therapeutics by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 68,830 shares of the company’s stock worth $266,000 after acquiring an additional 7,055 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC raised its position in Voyager Therapeutics by 100.3% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 205,732 shares of the company’s stock worth $794,000 after acquiring an additional 103,016 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.